Emeryville, Calif. August 27, 2024’ 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT, or the Company), a leading clinical-stage genetic medicines company, has announced its plans to host a 4D-150 Wet AMD Development Day on September 18, 2024, at 4:15 p.m. ET. This significant event underscores 4DMT’s commitment to advancing innovative genetic treatments for large market diseases, particularly through its promising candidate, 4D-150, aimed at treating wet age-related macular degeneration (wet AMD).
This upcoming Development Day will serve as a deep dive into the progress and future prospects of 4D-150, a cutting-edge intravitreal gene therapy. Wet AMD is a prevalent and severe eye condition that causes vision loss, predominately affecting older adults. Traditional treatments involve frequent and invasive ocular injections, presenting a heavy treatment burden for patients.
Positive Phase 2 PRISM Interim Results
The announcement follows closely on the heels of highly encouraging data from the PRISM Phase 2 Clinical Trial. On July 17, 2024, 4DMT disclosed initial interim 24-week landmark data from the Population Extension cohort of the PRISM study. This cohort evaluated intravitreal 4D-150 in a broad wet AMD patient population, and the results were presented by Dr. Raj K. Maturi in an oral presentation
Comments